Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogen inactivation techniques.

J P R Pelletier1, S Transue, E L Snyder

  • 1Department of Transfusion Medicine, Yale University School of Medicine, Yale-New Haven Hospital, New Haven, CT 06510-3202, USA.

Best Practice & Research. Clinical Haematology
|December 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Problems with irradiators.

Vox sanguinis·2009
Same author

Universal pre-storage leukoreduction--A defensible use of hospital resources: the Yale-New Haven Hospital experience.

Developments in biologicals·2005
Same author

Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells.

Cytotherapy·2002
Same author

Reducing the risk of blood transfusion.

Hematology. American Society of Hematology. Education Program·2001
Same author

hADA3 is required for p53 activity.

The EMBO journal·2001
Same author

Topical platelet growth factor therapy: of lotions and potions.

Transfusion·2001
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Developing pathogen-reduction technologies for blood products is crucial for safety. Various methods target specific blood components, aiming to eradicate pathogens without harming cells or creating toxins.

Area of Science:

  • Blood safety and transfusion medicine
  • Microbiology and infectious diseases
  • Biotechnology and chemical engineering

Background:

  • The critical need for pathogen-free blood supply drives innovation in inactivation technologies.
  • Current approaches aim to eliminate pathogens without compromising blood cell viability or introducing toxic byproducts.
  • A 'one-size-fits-all' strategy is insufficient; component-specific technologies are being developed.

Purpose of the Study:

  • To review diverse pathogen-reduction technologies for blood products.
  • To elucidate the mechanisms of action for various inactivation agents.
  • To assess the efficacy, toxicology, and regulatory considerations of these systems.

Main Methods:

  • Discussion of solvent detergent, methylene blue, psoralens (amotosalen), S-303, Inactine, and riboflavin treatments.

Related Experiment Videos

  • Analysis of pathogen inactivation mechanisms targeting nucleic acids or disrupting pathogen membranes.
  • Review of studies on efficacy against specific pathogen types (bacteria, viruses) and component compatibility.

    • Main Results:

    • Technologies like amotosalen for platelets and S-303/Inactine for red blood cells are under development.
    • Riboflavin shows potential for inactivating all three blood components (plasma, platelets, red blood cells).
    • Mechanisms involve nucleic acid targeting or membrane disruption, with efficacy varying by pathogen characteristics.

    Conclusions:

    • Pathogen reduction in blood products is an evolving field with ongoing research and development.
    • Toxicology and the formation of photoproducts remain key areas of investigation.
    • Regulatory oversight is essential for evaluating the safety and efficacy of new pathogen-reduction technologies.